As previously reported, the Federal Court of Appeal (FCA) dismissed Apotex’s appeal of a judicial review decision of the Therapeutic Products Directorate (TPD) which required Apotex to submit additional information concerning products manufactured or tested in Apotex’s facilities in India. The FCA found that the Federal Court made no reviewable error in its conclusion that the TPD’s decision was not improperly motivated. On February 22, 2019, the Supreme Court dismissed Apotex’s application for leave to appeal (docket No. 38336).
Related Publications & Articles
-
Supreme Court of Canada agrees to hear challenge to “multi-Crown” class actions under the BC Opioid Damages and Health Care Costs Recovery Act
The Supreme Court of Canada has granted Sanis Health, Shoppers Drug Mart, Sandoz Canada, and McKesson Canada leave to appeal Sandoz Canada v British Columbia, 2023 BCCA 306.Read More -
FCA dismisses appeal, patent not listable against STELARA SNDS
On November 21, 2023, the Federal Court of Appeal (FCA) dismissed Janssen’s appeal: Janssen Inc v Canada (Health), 2023 FCA 229.Read More -
Federal Court of Appeal dismisses appeal relating to Minister of Health’s decision to disclose records pursuant to Access to Information Act request
On November 1, 2023, the Federal Court of Appeal (FCA) dismissed Actial’s appeal from an application for judicial review of the Minister of Health’s decision to disclose records pursuant to a request...Read More